PMID- 22873625
OWN - NLM
STAT- MEDLINE
DCOM- 20130104
LR  - 20211021
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 32 Suppl 2
DP  - 2012 Aug 8
TI  - Current status of hepatocellular carcinoma treatment in Japan: practical use of 
      sorafenib (Nexavar(R)).
PG  - 25-35
AB  - The efficacy of sorafenib in hepatocellular carcinoma (HCC) has been demonstrated 
      in two pivotal clinical trials: the European SHARP trial and a second trial that 
      recruited patients in the Asia-Pacific region. Sorafenib was approved for the 
      treatment of advanced HCC in Japan based on the results of these studies. This 
      article presents experiences with sorafenib in patients with HCC at three 
      institutions in Japan, representing the viewpoints of a liver surgeon and a 
      hepatologist at university hospitals, and a hepatologist at a community hospital. 
      The three physicians discuss representative cases and current clinical practice 
      at their institutions, and their recommendations for the use of sorafenib in the 
      wider clinical setting. Overall, the experiences at these institutions show that 
      sorafenib is most effective when administered for a long time, and the management 
      of adverse events (AEs) [including dose-reduction and modification] is critical 
      to achieving high levels of adherence to treatment. A team-focussed treatment 
      strategy that includes patient counselling and follow-up can contribute to 
      managing AEs to ensure successful continuation of sorafenib therapy. In addition, 
      a proposed definition of unresponsiveness to transarterial chemoembolization and 
      the implications of treatment lag on the outcomes of sorafenib therapy, as well 
      as measures for the prevention and treatment of hand-foot skin reaction are 
      discussed.
FAU - Kokudo, Norihiro
AU  - Kokudo N
AD  - Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate 
      School of Medicine, University of Tokyo, 7-3-1 Hongo,Bunkyo-ku, Tokyo, Japan. 
      KOKUDO-2SU@h.u-tokyo.ac.jp
FAU - Nakajima, Junta
AU  - Nakajima J
FAU - Hatano, Etsuro
AU  - Hatano E
FAU - Numata, Kazushi
AU  - Numata K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Benzenesulfonates/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Hepatocellular/*drug therapy/pathology
MH  - Clinical Trials as Topic
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Japan
MH  - Liver Neoplasms/*drug therapy/pathology
MH  - Medication Adherence
MH  - Niacinamide/analogs & derivatives
MH  - Patient Education as Topic
MH  - Phenylurea Compounds
MH  - Pyridines/administration & dosage/adverse effects/*therapeutic use
MH  - Sorafenib
MH  - Time Factors
EDAT- 2012/08/10 06:00
MHDA- 2013/01/05 06:00
CRDT- 2012/08/10 06:00
PHST- 2012/08/10 06:00 [entrez]
PHST- 2012/08/10 06:00 [pubmed]
PHST- 2013/01/05 06:00 [medline]
AID - 6 [pii]
AID - 10.1007/BF03265494 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2012 Aug 8;32 Suppl 2:25-35. doi: 10.1007/BF03265494.